Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies

2017 NCCN Annual Conference

Leo I. Gordon, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses novel immunomodulatory agents and standard treatment options for patients with relapsed or refractory Hodgkin lymphoma.

Margaret A. Tempero, MD, on Pancreatic Cancer: Active Systemic Treatment

Margaret A. Tempero, MD, of the UCSF Helen ...

Hematologic Malignancies

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines

Ruben A. Mesa, MD, of the Mayo Clinic Cance...

Issues in Oncology

Paul M. Cinciripini, PhD, on Smoking Cessation in Patients With Cancer

Paul M. Cinciripini, PhD, of The University...

Head and Neck Cancer

David G. Pfister, MD, on HPV and Head and Neck Cancer

David G. Pfister, MD, of Memorial Sloan Ket...

Bladder Cancer

Elizabeth R. Plimack, MD, on Bladder Cancer: Management Updates

Elizabeth R. Plimack, MD, of Fox Chase Canc...

Sep

Today In Oncology

Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies

Related Videos

Margaret A. Tempero, MD, on Pancreatic Cancer: Active Systemic Treatment

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines

Paul M. Cinciripini, PhD, on Smoking Cessation in Patients With Cancer

David G. Pfister, MD, on HPV and Head and Neck Cancer

Elizabeth R. Plimack, MD, on Bladder Cancer: Management Updates

Elderly Patients With Advanced Colorectal Cancer Treated With Adjuvant Oxaliplatin Plus Fluoropyrimidines

Osimertinib vs Platinum/Pemetrexed in Patients With EGFR T790M Advanced NSCLC

Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer

Does Binimetinib Improve Progression-Free Survival in Recurrent or Persistent Low-Grade Serous Ovarian Carcinomas

Association of Adjuvant Endocrine Therapy With Overall Survival in Small HR-Positive, HER2-Negative Breast Cancer